Quick Answer
AN2 Therapeutics, Inc. reported Cash and Equivalents of $19.94 million for fiscal year 2025.
AN2 Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $19.94M | -6.6% |
| 2024 | $21.35M | +36.5% |
| 2023 | $15.65M | -42.5% |
| 2022 | $27.22M | +125.0% |
| 2021 | $12.10M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $18.00M | -46.3% | -1.2% |
| June 30, 2025 | $18.22M | -31.9% | -8.8% |
| March 31, 2025 | $19.98M | -19.1% | -6.4% |
| December 31, 2024 | $21.35M | +36.5% | -36.3% |
| September 30, 2024 | $33.50M | +2.7% | +25.2% |
| June 30, 2024 | $26.77M | -34.4% | +8.4% |
| March 31, 2024 | $24.69M | -7.5% | +57.8% |
| December 31, 2023 | $15.65M | -42.5% | -52.0% |
- AN2 Therapeutics, Inc. showed a decrease of -6.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2021–2025 period, AN2 Therapeutics, Inc.’s cash and equivalents has grown by 64.8% (from $12.10 million to $19.94 million).
- The most recent figure is from AN2 Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: